Premium
Prognostic significance of clinical and 18 F‐FDG PET/CT parameters for post‐distant metastasis survival in head and neck squamous cell carcinoma patients
Author(s) -
Cho JaeKeun,
Hyun Seung Hyup,
Choi Joon Young,
Choi Nayeon,
Kim MinJi,
Lee SeHoon,
Baek KwanHyuck,
Jeong HanSin
Publication year - 2016
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.24412
Subject(s) - medicine , positron emission tomography , head and neck squamous cell carcinoma , standardized uptake value , proportional hazards model , metastasis , head and neck cancer , primary tumor , oncology , radiology , distant metastasis , fluorodeoxyglucose , cancer , nuclear medicine
Distant metastasis (M1) to vital organs remains a major cause of death in patients with head and neck squamous cell carcinomas (HNSCC). Clinically the survival periods vary in individual M1 HNSCC patients and a prognostic indicator has not been fully studied. Here, we evaluated the prognostic factors for survival including 18 F‐fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) parameters in M1 HNSCC patients. Methods The study included 108 patients with newly diagnosed M1 HNSCC (68 during clinical courses, 40 at presentation) who underwent FDG PET/CT. Maximum standardized uptake value (SUVmax) of metastatic tumors was measured by FDG PET/CT. Associations of primary tumor or metastatic tumor variables with overall survival were assessed with Cox regression models. Results Multivariate analyses demonstrated that nasopharynx primary and incomplete response of loco‐regional disease to treatment were significant prognostic factors. In addition, adverse prognostic factors included short distant metastasis‐free period (<10 months), high number (≥5), and high PET SUVmax (≥6.3) of metastatic lesions. The patients with at least one of these adverse features had a median survival <14 months. Conclusion PET SUVmax of the metastatic tumors in M1 HNSCC patients can be a good predictor for survival. J. Surg. Oncol. 2016;114:888–894 . © 2016 2016 Wiley Periodicals, Inc.